KoBioLabs, Inc

A348150

KR7348150004

Food Processing

End-of-day quote Korea S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
7,470 ^KRW	-2.99%		-5.08%	-12.22%

2022	5,607,000 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-NOV-2022.	CI
2022	KoBioLabs, Inc announced that it has received KRW 10.000016 billion in funding from E-MART Inc.	CI

KoBioLabs,Inc has completed an IPO in the amount of KRW 30 billion.

November 12, 2020 at 05:00 am

KoBioLabs,Inc has completed an IPO in the amount of KRW 30 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,000,000 PriceRange: KRW 15000 Discount Per Security: KRW 750 Transaction Features: Sponsor Backed Offering

Latest news about KoBioLabs, Inc

5,607,000 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-NOV-2022.	17/11/22	CI
KoBioLabs, Inc announced that it has received KRW 10.000016 billion in funding from E-MART Inc.	05/04/22	CI
KoBioLabs to Raise $8 Million via Stock Offering	30/03/22	MT
KoBioLabs, Inc announced that it expects to receive KRW 10.000016 billion in funding from E-MART Inc.	28/03/22	CI
KoBioLabs, Inc announced that it has received KRW 6.99999775 billion in funding from Stonebridge Ventures Inc., Industrial Bank of Korea, Investment Arm and other investors	29/12/21	CI
KoBioLabs, Inc announced that it has received KRW 4.64999775 billion in funding	28/12/21	CI
KoBioLabs, Inc announced that it expects to receive KRW 6.99999775 billion in funding from Stonebridge Ventures Inc., Industrial Bank of Korea, Investment Arm and other investors	20/12/21	CI
KoBioLabs, Inc announced that it has received KRW 44.4498035 billion in funding from Jaedam Inc., Cornerstone Investment Partners Co., Ltd. and other investors	18/11/21	CI
1,130,196 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-NOV-2021.	17/11/21	CI
Kobiolabs Targets Over $28 Million Through Stock Offering	11/11/21	MT
KoBioLabs, Inc announced that it expects to receive KRW 44.4498035 billion in funding from Jaedam Inc., Cornerstone Investment Partners Co., Ltd. and other investors	09/11/21	CI
KoBioLabs, Inc(KOSDAQ:A348150) added to S&P Global BMI Index	21/06/21	CI
213,600 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-MAY-2021.	17/05/21	CI
840,158 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-FEB-2021.	17/02/21	CI
845,970 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-JAN-2021.	17/01/21	CI
2,525,978 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-DEC-2020.	17/12/20	CI
KoBioLabs,Inc has completed an IPO in the amount of KRW 30 billion.	12/11/20	CI
KoBioLabs,Inc has filed an IPO.	03/07/20	CI
KoBioLabs, Inc announced that it has received KRW 4 billion in funding from CJ Cheiljedang Corporation	27/02/19	CI

Chart KoBioLabs, Inc

Duration

Period

More charts

Company Profile

KoBioLabs Inc is a Korea-based company mainly engaged in the development and sales of functional probiotics. The Company's products are sold under the names of Bioviom and Queens henna FOODOLOGY. The Company is also engaged in the development of new microbiome drugs. In addition, the Company engages in commissioned research. The Company sells its products in domestic and overseas markets.

Sector

Food Processing

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
KOBIOLABS, INC	-12.22%	105M
ZHEJIANG NHU COMPANY LTD.	+13.74%	8.18B
BELLRING BRANDS, INC.	+5.29%	7.53B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-0.42%	5.89B
THE SIMPLY GOOD FOODS COMPANY	-6.67%	3.7B
BYHEALTH CO., LTD	-10.75%	3.57B
XIAMEN KINGDOMWAY GROUP COMPANY	-8.21%	1.26B
HERBALIFE LTD.	-29.10%	1.08B
SIRIO PHARMA CO., LTD.	+14.92%	991M
USANA HEALTH SCIENCES, INC.	-12.46%	894M